Missouri physician warns against injecting unapproved gray-market peptides
MU Health Care's Regina DePietro says products sold as research chemicals lack the post-market surveillance that confirms identity and safety.
DO
By Daniel Okafor · Regulatory Correspondent
Oct 14 06:00 ETSource: STLPR
The wire
- 01Dr. Regina DePietro of MU Health Care told STLPR that online retailers and compounding pharmacies push unregulated peptides such as BPC-157, often labeled for research purposes only.
- 02She contrasts those products with FDA-reviewed GLP-1 drugs that passed animal studies, clinical trials and post-market surveillance, and urges patients to consult a physician first.
- 03DePietro allows that some of these compounds could eventually be approved, saying the research is not there yet; cited risks include contamination, immune reactions and fraudulent product.
From the source
Read at stlpr.orgCurious about gray market peptides? One Mizzou doctor says tread carefully
A University of Missouri physician is warning people about the potential dangers of injecting unregulated peptides that have not been approved by federal safety and health regulators.
